{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.13.', 'Appendix 13: Myasthenia Gravis Foundation of America Post-', 'Interventional Status', 'Note that a modified version of Change in Status (excludes \"Exacerbation\" and \"Died of MG\")', 'is used in this protocol (see Section 8.1.9).', 'MGFA Post-intervention Status (MGFA-PIS)', 'Complete Stable', 'The patient has had no symptoms or signs of MG for at least 1 year and has received no therapy', 'Remission (CSR) for MG during that time. There is no weakness of any muscle on careful examination by', 'someone skilled in the evaluation of neuromuscular disease. Isolated weakness of eyelid closure', 'is accepted.', 'Pharmacologic', 'The same criteria as for CSR except that the patient continues to take some form of therapy for', 'Remission (PR)', 'MG. Patients taking cholinesterase inhibitors are excluded from this category because their use', 'suggests the presence of weakness.', 'Minimal', 'The patient has no symptoms of functional limitations from MG but has some weakness on', 'Manifestations', 'examination of some muscles. This class recognizes that some patients who otherwise meet the', '(MM)', 'definition of CSR or PR do have weakness that is only detectable by careful examination.', 'MM-0', 'The patient has received no MG treatment for at least 1 year.', 'MM-1', 'The patient continues to receive some form of immunosuppression but no cholinesterase', 'inhibitors or other symptomatic therapy.', 'MM-2', 'The patient has received only low-dose cholinesterase inhibitors (<120 mg pyridostigmine/day)', 'for at least 1 year.', 'MM-3', 'The patient has received cholinesterase inhibitors or other symptomatic therapy and some form', 'of immunosuppression during the past year.', 'Change in Status', 'Improved (I)', 'A substantial decrease in pretreatment clinical manifestations or a sustained substantial', 'reduction in MG medications as defined in the protocol. In prospective studies, this should', 'be', 'defined as a specific decrease in QMG score.', 'Unchanged (U)', 'No substantial change in pretreatment clinical manifestations or reduction in MG medications', 'as defined in the protocol. In prospective studies, this should be defined in terms of a maximum', 'change in QMG score.', 'Worse (W)', 'A substantial increase in pretreatment clinical manifestations or a substantial increase in MG', 'medications as defined in the protocol. In prospective studies, this should be defined as a', 'specific increase in QMG score.', 'Exacerbation (E)', 'Patients who have fulfilled criteria of CSR, PR, or MM but subsequently developed clinical', 'findings greater than permitted by these criteria.', 'Died of MG (D of Patients who died of MG, of complications of MG therapy, or within 30 days after thymectomy.', 'MG)', 'List the cause (see Morbidity and Mortality table).', 'Page 92 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.14.', 'Appendix 14: Columbia-Suicide Severity Rating Scale -', 'Baseline/Screening (Version 1/14/09)', 'Page 1 of 3', 'To be completed by Study Site', 'Study Number: ALXN1210-MG-306', 'Subject ID:', 'Date Completed:', 'Completed by:', 'Evaluator (initials):', 'COLUMBIA-SUICIDE SEVERITY', 'RATING SCALE', '(C-SSRS)', 'Baseline/Screening Version', 'Version 1/14/09', 'Posner, K.; Brent, D.; Lucas, C.; Gould, M.; Stanley, B.; Brown, G.; Fisher, P.; Zelazny, J.;', 'Burke, A.; Oquendo, M.; Mann, J.', 'Disclaimer:', 'This scale is intended to be used by individuals who have received training in its administration The questions contained in', 'the Columbia-Suicide Severity Rating Scale are suggested probes. Ultimately, the determination of the presence of suicidal', 'ideation or behavior depends on the judgment of the individual administering the scale.', 'Definitions of behavioral suicidal events in this scale are based on those used in The Columbia Suicide History Form.', 'developed by John Mann, MD and Maria Oquendo, MD, Conte Center for the Neuroscience of Mental Disorders', '(CCNMD), New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY, 10032. (Oquendo M. A.,', 'Halberstam B. & Mann J. J., Risk factors for suicidal behavior: utility and limitations of research instruments. In M.B. First', '[Ed.] Standardized Evaluation in Clinical Practice, pp. 103 - 130, 2003.)', 'For reprints of the C-SSRS contact Kelly Posner, Ph.D., New York State Psychiatric Institute, 1051 Riverside Drive, New', 'York, New York, 10032; inquiries and training requirements contact posnerk@nyspi.columbia.edu', '\u00a9 2008 The Research Foundation for Mental Hygiene, Inc.', 'C-SSRS Baseline Screening - United States/English Mapi.', 'C-SSRS-BasalineScreening_AU5.1_eng-USor.doc', 'Page 93 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}